



Impressum

Steering committee


Domenico Alexakis, Swiss Biotech Association, Zurich
Oreste Ghisalba, CTI, Berne
Andrea Isler, SIX Swiss Exchange AG, Zurich
Heinz Müller, Swiss Federal Institute of Intellectual Property, Berne
Antje Runschke, Osec, Zurich
Jürg Zürcher, Ernst & Young Ltd., Basel

Further partners

Sheena Bethell, BaselArea, Basel
Tom Brooks, Biopolo Ticino, Bellinzona
Ori Schipper, Swiss National Science Foundation, Berne
Denis Grisel, Berne Capital Area, Berne
Daniel Gygax, biotechnet, MuttENZ
Lukas Huber, Greater Zurich Area AG, Zurich
Ariane Vlérick, BioAlps, Geneva
Herbert Reutimann, swiTT, Berne


Concept, layout and design

Thomas Peller, MediCom Publishing, Zurich




Swiss Biotech Report 2010


Capital investment in Swiss biotech companies



Number of biotech companies in Switzerland



Number of employees



Lonza's transformation into a life science company and its inclusion into the ICB Biotech Sector and the SXI LIFE SCIENCE® and SXI Bio+Medtech® indices at the SIX Swiss Exchange.

- Merck Serono's operations (a division of Merck Germany) which are operationally headquartered in Switzerland remain in the data analysis with regard to revenues, R&D expenses and employees.
- As some private companies do not disclose financial figures, the figures represent Ernst & Young's best estimate.
- All figures are headquarter-counted.